Invention Grant
- Patent Title: Method for predicting the response of non-small-cell lung carcinoma patients to a medicament
-
Application No.: US16633389Application Date: 2018-08-09
-
Publication No.: US11802315B2Publication Date: 2023-10-31
- Inventor: Robby Ruijtenbeek , Dirgje Maria Adriana Van Den Heuvel , Richard De Wijn , Joan Gertrudis Jacobus Victor Aerts , Adrianus Henricus Josephus Mathijssen
- Applicant: PamGene B.V. , Erasmus University Medical Center Rotterdam
- Applicant Address: NL 's-Hertogenbosch
- Assignee: PamGene B.V.,Erasmus University Medical Center Rotterdam
- Current Assignee: PamGene B.V.,Erasmus University Medical Center Rotterdam
- Current Assignee Address: NL 's-Hertogenbosch; NL Rotterdam
- Agency: Amster, Rothstein & Ebenstein LLP
- Priority: EP 185467 2017.08.09
- International Application: PCT/EP2018/071569 2018.08.09
- International Announcement: WO2019/030311A 2019.02.14
- Date entered country: 2020-01-23
- Main IPC: C12Q1/6886
- IPC: C12Q1/6886 ; C12Q1/48
Abstract:
The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.
Public/Granted literature
- US20200232043A1 METHOD FOR PREDICTING THE RESPONSE OF NON-SMALL-CELL LUNG CARCINOMA PATIENTS TO A MEDICAMENT Public/Granted day:2020-07-23
Information query
IPC分类:
